A team of medical scientists at the VIB-UGent Center for Medical Biotechnology has recently taken remedial steps towards the development of the cancer-targeted immunotherapy for offering protection against metastases. The research team has been successful in developing a treatment in mice that can successfully destroy a part of the tumor. In addition to this, the new form of cancer-targeted treatment will also help in stimulating the body’s immune system for attacking persistent cancer surviving cells.
The team of researchers has demonstrated that the treatment would also provide protection against the development of tumor formation in other parts of the body as well. The results of the research have been published in Nature Communications.
Treatments like radiotherapy and chemotherapy are effective in destroying the cancer cells. However, these treatments also tend to destroy the healthy cells of the human body. Developing on the given knowledge, the team of researchers went forward with looking for an effective way to provoke necroptosis in the cancer cells. Thus, this will help in teaching the healthy immune system of the body to fight against the disease by attacking the tumor cells. The team of researchers went ahead with exploring “MLKL” –a type of protein that plays a vital role in the process of necroptosis for the purpose of the research goal.
The leading member of the research team stated that they have been successful in developing the cancer-targeted immune therapy that can cause a part of the cancer cells to generate the MLKL protein and then, activate the body’s immune system. This will attack the tumor cells that must have survived after the initial treatment.
The given cancer-targeted research of treatments not only inhibits the growth of primary tumors but will also offer protection against disseminated and untreated tumors.